Google
APTOF 株価分析 — DMD DIGITAL HEALTH CONNECTIONS GROUP INC (Healthcare >> Biotechnology)
APTOF に関するよくある質問
APTOFのROE（自己資本利益率）は？
DMD DIGITAL HEALTH CONNECTIONS GROUP INCのROEは93.75%です。
APTOFの配当利回りは？
DMD DIGITAL HEALTH CONNECTIONS GROUP INCの配当利回りは0.00%です。
APTOFの品質スコア（Quality Score）は？
当社のAIはAPTOFの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
APTOFは今が買い時ですか？
当社AIのタイミングスコアは100点中1点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
APTOFはどのセクターに属しますか？
DMD DIGITAL HEALTH CONNECTIONS GROUP INCはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
APTOF AI Analysis Summary
Our AI summary for APTOF: DMD DIGITAL HEALTH CONNECTIONS GROUP INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 93.75%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 1/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.69
Price
0.00
(0.00%)
Day Change
|
|
|---|
APTOF, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 87 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.69 |
| PBV / Sector |
-0.16 / 5.20
|
| Earning Per Share | -9.98 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
3949.807385000000
|
| Average 1W Daily Value |
0.01 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:29 |
| Symbol | APTOF |
| Name | DMD DIGITAL HEALTH CONNECTIONS GROUP INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 2.55 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4.31 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 66 Wellington Street West, Toronto, ON, Canada, M5K 1E6
Phone: 647 479 9828
Website: https://www.aptose.com
Sector: Healthcare >> Biotechnology
Description: Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes. It has license agreements with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
